Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non Operating Income (2023 - 2025)

Historic Other Non Operating Income for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $23.8 million.

  • NewAmsterdam Pharma's Other Non Operating Income rose 40815.89% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year decrease of 72.96%. This contributed to the annual value of $38.6 million for FY2024, which is 28513.68% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Other Non Operating Income is $23.8 million, which was up 40815.89% from $8.6 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Other Non Operating Income peaked at $30.2 million during Q1 2024, and registered a low of -$13.8 million during Q1 2025.
  • Its 3-year average for Other Non Operating Income is $7.0 million, with a median of $4.7 million in 2024.
  • Examining YoY changes over the last 5 years, NewAmsterdam Pharma's Other Non Operating Income showed a top increase of 88624.06% in 2024 and a maximum decrease of 906111.11% in 2024.
  • NewAmsterdam Pharma's Other Non Operating Income (Quarter) stood at $10.2 million in 2023, then surged by 92.33% to $19.6 million in 2024, then rose by 21.54% to $23.8 million in 2025.
  • Its Other Non Operating Income was $23.8 million in Q3 2025, compared to $8.6 million in Q2 2025 and -$13.8 million in Q1 2025.